Response of the binding capacity of plasma testosterone-estradiol-binding globulin to norethindrone, 2 mg., and mestranol, 0.1 mg., in polycystic ovarian disease.
The binding capacity of plasma testosterone-estradiol-binding globulin (TeBG) and testosterone (T) levels were measured in four women with proved polycystic ovaries and three women with a clinical diagnosis of polycystic ovarian disease before, during, and after administration of norethindrone, 2 mg., and mestranol, 0.1 mg. (N + M)...
D002352:Carrier Proteins / Q000097:blood*; D004958:Estradiol / Q000097:blood; D004970:Estrone / Q000097:blood; D005260:Female; D012739:Gonadal Steroid Hormones / Q000502:physiology; D008656:Mestranol / Q000494:pharmacology* / Q000627:therapeutic use; D009640:Norethindrone / Q000494:pharmacology* / Q000627:therapeutic use; D011085:Polycystic Ovary Syndrome / Q000097:blood* / Q000188:drug therapy; D011241:Prednisone / Q000097:blood; D011485:Protein Binding / Q000187:drug effects*; D013739:Testosterone / Q000097:blood; D013974:Thyroxine / Q000502:physiology; D013997:Time Factors
D002352:Carrier Proteins; D012739:Gonadal Steroid Hormones; D004970:Estrone; D013739:Testosterone; D004958:Estradiol; D008656:Mestranol; D013974:Thyroxine; D009640:Norethindrone; D011241:Prednisone